Barclays Reinstates Tarsus Pharmaceuticals (TARS) at Overweight

Barclays analyst Glen Santangelo reinstates coverage on Tarsus Pharmaceuticals (NASDAQ: TARS) with a Overweight rating and a price target of $110.00.

For an analyst ratings summary and ratings history on Tarsus Pharmaceuticals click here. For more ratings news on Tarsus Pharmaceuticals click here.

Shares of Tarsus Pharmaceuticals closed at $78.23 yesterday.

You May Also Be Interested In

• Jefferies Starts Crane NXT (CXT) at Buy, 'Underappreciated Growth and Margin Story'
• BNP Paribas Exane Starts Nintendo Co Ltd. (7974:JP) (NTDOY) at Neutral
• JPMorgan Starts Dajin Heavy Industry (1081:HK) at Overweight